Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients.

Transplant Direct · 2017 · PMC5361562 · PMID 28349124

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

15 - 19 Two studies showed comparable numbers of AREs after induction with alemtuzumab and ATG, 16 , 19 2 others showed a trend toward lower rejection rates with alemtuzumab. 17 , 18 More detailed information on timing of AREs and mechanistic insights in AREs have not been published so far.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.